Spain sepsis mortality reaches 12.8% of the patients

-AstraZeneca, the AEC and the SEMICYUC organized the 5th year of severe Sepsis in the surgical patient

– the course became again a space to update and renew the septic patient knowledge, as well as to acquire clinical skills to deal with these patients with tools diagnóstico-terapéuticas.

Barcelona, June of 2011. AstraZeneca, ACS (Spanish Association of Surgeons) and SEMICYUC (Spanish society of medicine intensive, critical care and coronary unit) have organized a new edition of the advanced course 5th of severe Sepsis in the surgical patient. The Conference, which took place recently in Sitges, served to update and renew knowledge in septic patients through the analysis of the most recent scientific literature on this subject.

The course for surgeons in training, both active received the papers of professors of surgery and intensive care medicine. Among the most relevant issues addressed, they emphasized asepsis measures, guidelines for empirical antibiotic treatment of intra-abdominal infection, as well as measures of hemodynamic treatment and organic support for patients with severe sepsis.

Speakers participants in the course included Dr. Javier Arias, Coordinator of the section of surgical infection of the AEC and Professor at Complutense University of Madrid. In relation to the benefits of this course, Dr Arias pointed out its multidisciplinary and practical approach in the ability to apply knowledge to specific cases, while with regard to the characteristics of this Edition, it has highlighted the analysis of past cases and investigations in this area.

According to the AEC, sepsis is a disease whose incidence in Spain rate is 367 cases for every 100,000 adults per year and whose mortality reaches 12.8% among their patients. Currently, most employed strategies for its prevention are confined to rules of asepsis and antibiotic prophylaxis protocols, but says Dr. Arias, the great problem is the poor implementation of such standards by healthcare personnel ”.

Given the complexity of the study of the disease and its continuous evolution with respect to the emergence of resistance and new therapies for Dr. Arias intensive days like this involve a periodic review to a problem of vital importance ”.